DELCATH SYSTEMS INC

DCTHNASDAQ

🏆 #2277 by market capEarnings Nov 2US Equity

$395.09▲ $7.98 (+2.02%)

Simulated price

1h—

24h▲ 2.0%

7d—

14d—

30d—

1y—

🏦Market Cap

$594M

Small Cap

📈Revenue Growth (YoY)

+129.1%

High Growth

📊Gross Margin

87.0%

High

💵FCF Margin

18.4%

Healthy

⚖️P/S Ratio

6.2x

Fair

Otter Score

Weak

No chart data available for DCTH.

Trading Snapshot

Day Range: $392.55 – $396.97
52-Week Range: $8.12 – $17.39
Volume: $3.61B
Avg Volume: $2.89B
Shares Outstanding: 34.5M
Next Earnings: Oct 6, 2026

Fundamentals Snapshot

Annual Revenue: $85M
Last Q Revenue: $29M
P/E Ratio: 1565.5
P/S Ratio: 6.2x
EPS (TTM): $0.01
Dividend Yield: 0.00%

Why Investors Own DCTH

✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
✓Healthy economics — 48% gross margin and 21% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$85M▲ +48.8% YoY

Gross Margin (TTM)

48.1%▲ +3.1% YoY

Operating Income (TTM)

$18M▲ +48.8% YoY

Free Cash Flow (TTM)

$18M▲ +48.8% YoY

About DELCATH SYSTEMS INC

Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.

🦦